{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T01:28:36Z","timestamp":1773278916644,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2004,11,9]],"date-time":"2004-11-09T00:00:00Z","timestamp":1099958400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2005,1]]},"DOI":"10.1007\/s00520-004-0731-1","type":"journal-article","created":{"date-parts":[[2004,11,8]],"date-time":"2004-11-08T11:08:59Z","timestamp":1099912139000},"page":"57-65","source":"Crossref","is-referenced-by-count":41,"title":["Effectiveness and safety of oral extended-release oxymorphone for the treatment of cancer pain: a pilot study"],"prefix":"10.1007","volume":"13","author":[{"given":"Paul","family":"Sloan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neal","family":"Slatkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harry","family":"Ahdieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2004,11,9]]},"reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1177\/0091270004266487","volume":"44","author":"Ahdieh","year":"2004","unstructured":"Ahdieh H, Ma T, Babul N, Lee D (2004) Efficacy of oxymorphone extended release in postsurgical pain: a randomized clinical trial in knee arthroplasty. J Clin Pharmacol 44:767?776","journal-title":"J Clin Pharmacol"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1097\/00000542-199605000-00029","volume":"84","author":"American","year":"1996","unstructured":"American Society of Anesthesiologists (1996) A report by the American Society of Anesthesiologists Task Force on Pain Management, Cancer Pain Section. Anesthesiology 84:1243?1257","journal-title":"Anesthesiology"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1177\/009127007701700402","volume":"17","author":"Beaver","year":"1977","unstructured":"Beaver WT, Wallenstein SL, Houde RW, Rogers A (1977) Comparisons of the analgesic effects of oral and intramuscular oxymorphone and of intramuscular oxymorphone and morphine in patients with cancer. J Clin Pharmacol 17:186?198","journal-title":"J Clin Pharmacol"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1074\/jbc.M006352200","volume":"276","author":"Befort","year":"2001","unstructured":"Befort K, Filliol D, Decaillot FM, Gaveriaux-Ruff C, Hoehe MR, Kieffer BL (2001) A single nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signaling. J Biol Chem 276:3130?3137","journal-title":"J Biol Chem"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1200\/JCO.1996.14.5.1713","volume":"14","author":"Bruera","year":"1996","unstructured":"Bruera E, Sloan P, Mount B, Scott J, Suarez-Almazor M (1996) A randomized, double-blind, double-dummy, crossover trial comparing the safety and efficacy of oral sustained-release hydromorphone with immediate-release hydromorphone in patients with cancer pain. Canadian Palliative Care Clinical Trials Group. J Clin Oncol 14:1713?1717","journal-title":"J Clin Oncol"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1200\/JCO.1998.16.10.3222","volume":"16","author":"Bruera","year":"1998","unstructured":"Bruera E, Belzile M, Pituskin E, et al (1998) Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain. J Clin Oncol 16(10):3222?3229","journal-title":"J Clin Oncol"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1002\/1097-0142(19951001)76:7<1283::AID-CNCR2820760728>3.0.CO;2-0","volume":"76","author":"Cherny","year":"1995","unstructured":"Cherny NJ, Chang V, Frager G, et al (1995) Opioid pharmacotherapy in the management of cancer pain: a survey of strategies used by pain physicians for the selection of analgesic drugs and routes of administration. Cancer 76:1283?1293","journal-title":"Cancer"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3109\/07357909809032886","volume":"16","author":"Citron","year":"1998","unstructured":"Citron ML, Kaplan R, Parris WC, et al (1998) Long-term administration of controlled-release oxycodone tablets for the treatment of cancer pain. Cancer Invest 16:562?571","journal-title":"Cancer Invest"},{"key":"CR9","first-page":"446","volume":"11","author":"Cone","year":"1983","unstructured":"Cone EJ, Darwin WD, Buchwald WF, Gorodetzky CW (1983) Oxymorphone metabolism and urinary excretion in human, rat, guinea pig, rabbit, and dog. Drug Metab Dispos 11:446?450","journal-title":"Drug Metab Dispos"},{"key":"CR10","first-page":"213","volume":"11","author":"Cooper","year":"1994","unstructured":"Cooper SA, Fitzmartin R, Slywka J, et al (1994) Analgesic efficacy and safety of two oral controlled-release morphine preparations in orthopedic postoperative pain. Adv Ther 11:213?227","journal-title":"Adv Ther"},{"key":"CR11","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s002280050651","volume":"55","author":"Curtis","year":"1999","unstructured":"Curtis GB, Johnson GH, Clark P, et al (1999) Relative potency of controlled-release oxycodone and controlled-release morphine in a postoperative pain model. Eur J Clin Pharmacol 55:425?429","journal-title":"Eur J Clin Pharmacol"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/0885-3924(95)00123-9","volume":"10","author":"Dhaliwal","year":"1995","unstructured":"Dhaliwal HS, Sloan P, Arkinstall WW, et al (1995) Randomized evaluation of controlled-release codeine and placebo in chronic cancer pain. J Pain Symptom Manage 10:612?623","journal-title":"J Pain Symptom Manage"},{"key":"CR13","first-page":"116","volume":"125","author":"Eddy","year":"1959","unstructured":"Eddy NB, Lee LEJ (1959) The analgesic equivalence to morphine and relative side action liability of oxymorphone (4-hydroxydihydromorphinone). J Pharmacol Exp Ther 125:116?121","journal-title":"J Pharmacol Exp Ther"},{"key":"CR14","unstructured":"Endo Pharmaceuticals (2002) Clinical study report EN3202-019. Endo Pharmaceuticals, Chadds Ford, PA"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"204","DOI":"10.2165\/00126839-200304030-00012","volume":"4","author":"Endo","year":"2003","unstructured":"Endo\/Penwest (2003) Oxymorphone?Endo\/Penwest: EN 3202, EN 3203. Drugs R D 4:204?206","journal-title":"Drugs R D"},{"key":"CR16","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1200\/JCO.1993.11.5.967","volume":"11","author":"Finn","year":"1993","unstructured":"Finn JW, Walsh TD, MacDonald N, Bruera E, Krebs LU, Shepard KV (1993) Placebo-blinded study of morphine sulfate sustained-release tablets and immediate-release morphine sulfate solution in outpatients with chronic pain due to advanced cancer. J Clin Oncol 11:967?972","journal-title":"J Clin Oncol"},{"key":"CR17","unstructured":"Flockhart DA (2003) Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine. Available at: http:\/\/medicine.iupui.edu\/flockhart\/. Accessed 30 May 2003"},{"key":"CR18","unstructured":"Food and Drug Administration (2003) Guidance for industry. E6 Good Clinical Practice: Consolidated Guideline. U.S. Department of Health and Human Services. Available at: http:\/\/www.fda.gov\/cder\/guidance\/959fnl.pdf. Accessed 2 October 2003"},{"key":"CR19","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1213\/01.ANE.0000132548.91622.B3","volume":"99","author":"Gimbel","year":"2004","unstructured":"Gimbel J, Ahdieh H (2004) Efficacy and safety of oral immediate-release oxymorphone for postsurgical pain. Anesth Analg 99:1472?1477","journal-title":"Anesth Analg"},{"key":"CR20","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1002\/(SICI)1097-0142(19970401)79:7<1428::AID-CNCR21>3.0.CO;2-0","volume":"79","author":"Hagen","year":"1997","unstructured":"Hagen NA, Babul N (1997) Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer 79:1428?1437","journal-title":"Cancer"},{"key":"CR21","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0304-3959(97)00072-9","volume":"73","author":"Heiskanen","year":"1997","unstructured":"Heiskanen T, Kalso E (1997) Controlled-release oxycodone and morphine in cancer related pain. Pain 73:37?45","journal-title":"Pain"},{"key":"CR22","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0009-9236(98)90051-0","volume":"64","author":"Heiskanen","year":"1998","unstructured":"Heiskanen T, Kalso E, Olkkola KT (1998) Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther 64:603?611","journal-title":"Clin Pharmacol Ther"},{"key":"CR23","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1080\/02841860050215927","volume":"39","author":"Heiskanen","year":"2000","unstructured":"Heiskanen TE, Ruismaki PM, Seppala TA, Kalso EA (2000) Morphine or oxycodone in cancer pain? Acta Oncol 39:941?947","journal-title":"Acta Oncol"},{"key":"CR24","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1093\/hmg\/9.19.2895","volume":"9","author":"Hoehe","year":"2000","unstructured":"Hoehe MR, Kopke K, Wendel B, et al (2000) Sequence variability and candidate gene analysis in complex disease: association of mu opioid receptor gene variation with substance dependence. Hum Mol Genet 9(19):2895?2908","journal-title":"Hum Mol Genet"},{"key":"CR25","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1200\/JCO.2002.20.1.348","volume":"20","author":"Indelicato","year":"2002","unstructured":"Indelicato RA, Portenoy RK (2002) Opioid rotation in the management of refractory cancer pain. J Clin Oncol 20:348?352","journal-title":"J Clin Oncol"},{"key":"CR26","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s005200000153","volume":"8","author":"Kloke","year":"2000","unstructured":"Kloke M, Rapp M, Bosse B, Kloke O (2000) Toxicity and\/or insufficient analgesia by opioid therapy: risk factors and the impact of changing the opioid. A retrospective analysis of 273 patients observed at a single center. Support Care Cancer 8:479?486","journal-title":"Support Care Cancer"},{"key":"CR27","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0885-3924(95)00162-X","volume":"11","author":"Korte","year":"1996","unstructured":"Korte W, de Stoutz N, Morant R (1996) Day-to-day titration to initiate transdermal fentanyl in patients with cancer pain: short- and long-term experiences in a prospective study of 39 patients. J Pain Symptom Manage 11:139?146","journal-title":"J Pain Symptom Manage"},{"key":"CR28","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1124\/dmd.32.4.447","volume":"32","author":"Lalovic","year":"2004","unstructured":"Lalovic B, Phillips B, Risler LL, Howald W, Shen DD (2004) Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos 32:447?454","journal-title":"Drug Metab Dispos"},{"key":"CR29","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1002\/(SICI)1097-0142(19980315)82:6<1167::AID-CNCR23>3.0.CO;2-3","volume":"82","author":"Lawlor","year":"1998","unstructured":"Lawlor PG, Turner KS, Hanson J, Bruera ED (1998) Dose ratio between morphine and methadone in patients with cancer pain: a retrospective study. Cancer 82:1167?1173","journal-title":"Cancer"},{"key":"CR30","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1097\/00000542-199904000-00016","volume":"90","author":"Lotsch","year":"1999","unstructured":"Lotsch J, Weiss M, Ahne G, Kobal G, Geisslinger G (1999) Pharmacokinetic modeling of M6G formation after oral administration of morphine in healthy volunteers. Anesthesiology 90:1026?1038","journal-title":"Anesthesiology"},{"key":"CR31","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1016\/S0140-6736(99)03528-X","volume":"353","author":"McQuay","year":"1999","unstructured":"McQuay H (1999) Opioids in pain management. Lancet 353(9171):2229?2232","journal-title":"Lancet"},{"key":"CR32","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1021\/jm000381r","volume":"44","author":"Metzger","year":"2001","unstructured":"Metzger TG, Paterlini MG, Ferguson DM, Portoghese PS (2001) Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the ?address? recognition locus. J Med Chem 44:857?862","journal-title":"J Med Chem"},{"key":"CR33","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2165\/00003495-200363010-00002","volume":"63","author":"Nicholson","year":"2003","unstructured":"Nicholson B (2003) Responsible prescribing of opioids for the management of chronic pain. Drugs 63:17?32","journal-title":"Drugs"},{"key":"CR34","unstructured":"Northrup Grumman (2004) International Conference on Harmonization. Medical Dictionary for Regulatory Activities (MedDRA). http:\/\/www.meddramsso.com\/NewWeb2003\/index.htm"},{"key":"CR35","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1191\/0269216303pm658oa","volume":"17","author":"Quigley","year":"2003","unstructured":"Quigley C, Joel S, Patel N, Baksh A, Slevin M (2003) Plasma concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide and their relationship with analgesia and side effects in patients with cancer-related pain. Palliat Med 17:185?190","journal-title":"Palliat Med"},{"key":"CR36","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1046\/j.1440-1681.2000.03293.x","volume":"27","author":"Ravenscroft","year":"2000","unstructured":"Ravenscroft P, Schneider J (2000) Bedside perspectives on the use of opioids: transferring results of clinical research into practice. Clin Exp Pharmacol Physiol 27:529?532","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"CR37","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/S0002-9343(02)01363-3","volume":"113","author":"Rogers","year":"2002","unstructured":"Rogers JF, Nafziger AN, Bertino JS Jr (2002) Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. Am J Med 113:746?750","journal-title":"Am J Med"},{"key":"CR38","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0304-3959(97)00093-6","volume":"73","author":"Ross","year":"1997","unstructured":"Ross FB, Smith MT (1997) The intrinsic antinociceptive effects of oxycodone appear to be kappa-opioid receptor mediated. Pain 73:151?157","journal-title":"Pain"},{"key":"CR39","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1300\/J011v14n02_03","volume":"14","author":"Sloan","year":"1999","unstructured":"Sloan P, Melzack R (1999) Long-term patterns of morphine dosage and pain intensity among cancer patients. Hosp J 14:35?47","journal-title":"Hosp J"},{"key":"CR40","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S0885-3924(98)00044-X","volume":"16","author":"Sloan","year":"1998","unstructured":"Sloan PA, Moulin DE, Hays H (1998) A clinical evaluation of transdermal therapeutic system fentanyl for the treatment of cancer pain. J Pain Symptom Manage 16:102?111","journal-title":"J Pain Symptom Manage"},{"key":"CR41","doi-asserted-by":"crossref","unstructured":"Thirlwell MP, Sloan PA, Maroun JA, et al (1989) Pharmacokinetics and clinical efficacy of oral morphine solution and controlled-release morphine tablets in cancer patients. Cancer 63 [11 Suppl]:2275?2283","DOI":"10.1002\/1097-0142(19890601)63:11<2275::AID-CNCR2820631136>3.0.CO;2-4"},{"key":"CR42","doi-asserted-by":"crossref","first-page":"7752","DOI":"10.1073\/pnas.96.14.7752","volume":"96","author":"Uhl","year":"1999","unstructured":"Uhl GR, Sora I, Wang Z (1999) The mu opiate receptor as a candidate gene for pain: polymorphisms, variations in expression, nociception, and opiate responses. Proc Natl Acad Sci U S A 96(14):7752?7755","journal-title":"Proc Natl Acad Sci U S A"},{"key":"CR43","doi-asserted-by":"crossref","first-page":"34624","DOI":"10.1074\/jbc.M104083200","volume":"276","author":"Wang","year":"2001","unstructured":"Wang D, Quillan JM, Winans K, Lucas JL, Sadee W (2001) Single nucleotide polymorphisms in the human mu opioid receptor gene alter basal G protein coupling and calmodulin binding. J Biol Chem 276(37):34624?34630","journal-title":"J Biol Chem"},{"key":"CR44","unstructured":"World Health Organization (1990) Cancer pain relief and palliative care. Expert Committee. Technical report series no. 804. World Health Organization, Geneva"},{"key":"CR45","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1399-6576.1997.tb04623.x","volume":"41","author":"Yaksh","year":"1997","unstructured":"Yaksh TL (1997) Pharmacology and mechanisms of opioid analgesic activity. Acta Anaesthesiol Scand 41(1 Pt 2):94?111","journal-title":"Acta Anaesthesiol Scand"},{"key":"CR46","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1517\/14656566.4.4.493","volume":"4","author":"Zeppetella","year":"2003","unstructured":"Zeppetella G, Ribeiro MD (2003) Pharmacotherapy of cancer-related episodic pain. Expert Opin Pharmacother 4:493?502","journal-title":"Expert Opin Pharmacother"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-004-0731-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-004-0731-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-004-0731-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T01:59:08Z","timestamp":1559095148000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-004-0731-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,11,9]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1]]}},"alternative-id":["731"],"URL":"https:\/\/doi.org\/10.1007\/s00520-004-0731-1","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,11,9]]}}}